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IMPACT OF COMMUNITY-ACQUIRED 
PNEUMONIA TREATMENT GUIDELINES ON 
LENGTH OF STAY AND COST
Merchant SV, Mullins CD, Cooke CE
Pharmacy Practice and Science, University of Maryland, School 
of Pharmacy, Baltimore, MD, USA
Community-acquired pneumonia (CAP) is associated
with significant morbidity, mortality and utilization of
health care resources. Strategies for decreasing cost of
treating CAP include identifying low-risk patients and
promoting the use of appropriate antibiotic therapy. Three
MCOs in the Greater Baltimore Washington DC area uti-
lized a prediction rule for triaging patients with CAP
(outpatient, inpatient or ICU), based on the risk for mor-
tality, and jointly developed a treatment guideline based
on the triaging. The guidelines were distributed to physi-
cians within the three plans. OBJECTIVE: To determine
the impact of the CAP treatment guidelines on LOS and
cost. METHODS: Health and demographic information
were abstracted from medical chart review and merged
with billing data from these insurance plans for randomly
selected patients. LOS and costs were compared for the
two periods: pre-intervention and post-intervention. RE-
SULTS: A decrease in LOS was observed in the post-inter-
vention period for all the three plans by 0.5 days (P 
0.69), 0.6 days (P  0.43), and 0.4 days (P  0.01) re-
spectively. There was a decrease in the mean amounts
billed for the three plans. The decrease in the mean
amounts billed was $2,257 (P  0.01), $1,801 (P 
0.77), and $259 (P  0.13) respectively. Results suggest
that there may have been a favorable impact on both the
LOS and cost across the three plans, but the results were
not statistically significant. The guidelines had no impact
on readmission or mortality. CONCLUSION: A reduc-
tion in LOS and cost was observed in all the three plans.
Treatment guidelines provide a useful tool to reduce vari-
ability in rates of hospitalization and aid physicians in
making proper decisions regarding treatment.
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USE OF ESTROGEN REPLACEMENT THERAPY IN 
MARYLAND MEDICAID FEMALES
Huang X, Weiss SR, Zuckerman IH, Hsu VD
School of Pharmacy, University of Maryland, Baltimore, MD, 
USA
OBJECTIVES: To describe use of estrogen replacement
therapy (ERT) among Maryland Medicaid females and
to identify factors associated with its use and discontinu-
ation. METHODS: This study was conducted using
Medicaid claims data to identify women, age 45 years or
older, with at least two years of continuous Medicaid eli-
gibility between October 1, 1995 and September 30,
1998. Drug use was based on prescription claims and
clinical characteristics were based on medical, institu-
tional, and prescription claims. RESULTS: 60,531 female
recipients were eligible for the study with a mean age of
68 years (SD  12.9). The overall ERT prevalence was
14%. ERT use was the highest in the 45–54 age group
(23.9%, P  0.001) and higher among white than non-
white women (15.7% vs. 12.9%, P  0.001). Unop-
posed estrogen products were dispensed to 70.5% of
ERT users (average duration  142 days). The remainder
used estrogen-progestin combinations and had shorter
duration (average  85 days). ERT use was higher among
women with osteoporosis, ischemic heart disease, hyper-
tension, hyperlipidemia, or diabetes as compared to pa-
tients without these conditions (P  0.001). ERT use was
low among breast cancer patients (P  0.001), whereas a
diagnosis of endometrial cancer, or thromboembolic dis-
ease was unrelated to ERT use. Using proportional haz-
ards models, discontinuation of ERT was associated with
nonwhite race (P  0.001) and estrogen sensitive cancers
(P  0.001). Conversely, having claims indicative of os-
teoporosis, ischemic heart disease, hypertension, or hy-
perlipidemia was unrelated to discontinuation of ERT.
CONCLUSION: ERT use in this population was low
compared to estimates for US women 50 or older based
on NHANES III. Intervention should be considered to in-
crease ERT use among women with cardiac risk factors
and to improve long-term compliance. 
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STATISTICAL METHOD FOR MODELING DUAL 
SELECTION BIAS: WOODWORK EFFECT AND 
DRUG SELECTION BIAS AMONG 
MULTIPLE ALTERNATIVES
Shi L, McCombs JS
Department of Pharmaceutical Economics and Policy, School 
of Pharmacy, University of Southern California, Los Angeles, 
CA, USA
BACKGROUND: The California Medicaid program
(Medi-Cal) added fluoxetine and paroxetine to its formu-
lary in May 1996. This policy change created two types
of selection bias that must be accounted for in compari-
sons across drugs. First, new patients may have sought
treatment in response to the change (woodwork effect).
Second, prescribing patterns may have also changed
(drug selection bias). OBJECTIVES: This study used a
Dual- method to adjust jointly for these two selectivity
biases in evaluating the effects of alternative antidepres-
sant therapies on health care costs. METHODS: All pa-
tients with a recorded diagnosis of major depression
(MDD) between 04/01/1994 and 01/31/1999 were se-
lected from the Medi-Cal paid claims system. Results
from the Dual- method were compared with the stan-
dard Heckman-Lee method. RESULTS: The formulary
policy change was a statistically significant factor in the
woodwork effect and altered antidepressant selection
patterns. In the second-stage cost models with double s,
